Method for treating sars-cov-2 infectious disease
AssigneeResearch & Business Foundation Sungkyunkwan University
InventorWonhwa LEE
Life of this patent
Estimating the term…
Abstract
Disclosed are a composition for diagnosis of SARS-CoV-2 infectious disease, a diagnostic kit, a method for providing information for diagnosis, a method for screening a therapeutic agent, and a composition for prevention or treatment, wherein it is expected that the diagnosis or prognostic prediction of the severity of SARS-CoV-2 infectious disease can be attained and the control of expression and activity of TOX, which is a marker, can be advantageously used in the development of a therapeutic agent for SARS-CoV-2 infectious disease.
Claims7
A method for treating SARS-CoV-2 infectious disease, the method comprising administering to a subject a composition comprising an agent for inhibiting expression or activity of thymocyte selection associated high mobility group box (TOX) protein or a polynucleotide encoding TOX protein.
A method for treating a severe SARS-CoA-2 patient, the method comprising:
- measuring the protein level or mRNA expression level of thymocyte selection associated high mobility group box (TOX) in a biological sample isolated from a SARS-CoV-2 infected patient;
- comparing the measured protein level or mRNA expression level of TOX with that of a normal control group;
- and
- administering a composition for treatment of SARS-CoV-2 infection to a SARS-CoV-2 infected patient, from which a biological sample with a higher protein level or mRNA expression level of TOX than the normal control group is isolated.
Dependencies are inferred from the claim text.